FrancophonIA/ELRC3.0 huggingface dataset:
English: If you do not tolerate the dose, the doctor may decrease the dose to the previous step.
Croatian: Ako ne podnosite određenu dozu, liječnik će je možda smanjiti na prethodnu dozu.
English: If the patient tolerates the dose, the doctor may increase the dose every week by 200 micrograms twice daily, up to a maximum of 1,600 micrograms twice daily.
Croatian: Ako bolesnik dobro podnosi dozu, liječnik je može povećavati svakoga tjedna za 200 mikrograma dvaput dnevno, do najveće dopuštene doze od 1600 mikrograma dvaput dnevno.
English: • If the patient tolerates the dose, the dose can be increased weekly by 200 micrograms twice daily, up to a maximum of 1,600 micrograms twice daily.
Croatian: • Ako je bolesnik dobro podnosi, doza se može povećavati na tjednoj osnovi za 200 mikrograma dvaput dnevno, do najveće dopuštene doze od 1600 mikrograma dvaput dnevno.
English: This overview was last updated in 01-2019.
Croatian: Ovaj sažetak je posljednji put ažuriran u 01-2019.
English: This was switched to a full marketing authorisation on 18 June 2018.
Croatian: To je odobrenje pretvoreno u potpuno odobrenje za stavljanje lijeka u promet 18. lipnja 2018.
English: Treatment may be interrupted or stopped altogether in case of certain side effects.
Croatian: Liječenje se može privremeno prekinuti ili trajno obustaviti u slučaju određenih nuspojava.
English: Further information on Blincyto can be found on the Agency's website: ema.europa.eu/medicines/Human/EPAR/blincyto.
Croatian: Više informacija o lijeku Blincyto možete naći na internetskim stranicama Agencije: ema.europa.eu/medicines/Human/EPAR/blincyto.
English: What measures are being taken to ensure the safe and effective use of Blincyto?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Blincyto?
English: Results showed that around 78% of patients did not have measurable residual cancer cells after treatment with Blincyto.
Croatian: Rezultati su pokazali da oko 78 % bolesnika nije imalo mjerljive rezidualne stanice raka nakon liječenja lijekom Blincyto.
English: Patients will also be provided with a patient alert card.
Croatian: Bolesnici će dobiti i karticu s upozorenjima za bolesnike.
English: Other information about Blincyto
Croatian: Ostale informacije o lijeku Blincyto
English: Patients should also be given chemotherapy medicines injected in the spine area to prevent leukaemia in the nervous system.
Croatian: Bolesnicima treba također dati kemoterapijske lijekove, i to ubrizgavanjem u područje kralježnice, kako bi se spriječila leukemija u živčanom sustavu.
English: In most patients whose ALL improved, there was no evidence of cancer cells left.
Croatian: U većine bolesnika s poboljšanjem ALL-a nije bilo dokaza o preostalim stanicama raka.
English: Blincyto has also been studied in a main study in 116 patients with minimal residual disease.
Croatian: Blincyto je također ispitivan u glavnom ispitivanju u 116 bolesnika s minimalnom rezidualnom bolešću.
English: The most common side effects with Blincyto (which may affect more than 1 in 10 people) are infections, fever, infusion-related reactions (like fever, changes in blood pressure and rash), headache, febrile neutropenia (low levels a type of white blood cell counts called neutrophils with fever), anaemia (low red blood cell counts), oedema (swelling because of fluid retention), neutropenia, leukopenia (low levels of white blood cell), thrombocytopenia (low platelet count), blood tests showing changes in liver function, tremor (shaking), back pain, chills, low blood pressure, low levels of immunoglobulins (antibodies), cytokine release syndrome (a potentially life-threatening condition that can cause fever, vomiting, shortness of breath, pain and low blood pressure), rapid heartbeat, insomnia (difficulty sleeping), pain in the arms and legs, cough and rash.
Croatian: Najčešće nuspojave lijeka Blincyto (koje se mogu javiti u više od 1 na 10 osoba) jesu infekcije, vrućica, reakcije povezane s infuzijom (kao što su vrućica, promjene krvnog tlaka i osip), glavobolja, febrilna neutropenija (niska razina vrste bijelih krvnih stanica naziva neutrofili praćena vrućicom), anemija (pad broja crvenih krvnih stanica), edem (oticanje zbog zadržavanja tekućine), neutropenija, leukopenija (niske razine bijelih krvnih stanica), trombocitopenija (smanjen broj trombocita), promjene u funkciji rada jetre vidljive u krvnim pretragama, tremor (drhtanje), bol u leđima, zimica, nizak krvni tlak, niske razine imunoglobulina (protutijela), sindrom otpuštanja citokina (stanje potencijalno opasno za život koje može prouzročiti simptome kao što su vrućica, povraćanje, nedostatak zraka, bolovi i nizak krvni tlak), brzi otkucaji srca, nesanica (poteškoće sa spavanjem), bol u rukama i nogama, kašalj i osip.
English: Further information on the orphan designation can be found here: ema.europa.eu/en/medicines/human/orphan-designations.
Croatian: Više informacija o statusu lijeka za liječenje rijetkih i teških bolesti možete naći ovdje: ema.europa.eu/en/medicines/human/orphan-designations.
English: The study found that ALL improved in 43% (81 out of 189) of patients given Blincyto.
Croatian: U ispitivanju je utvrđeno poboljšanje ALL-a u 43 % (81 od 189) bolesnika liječenih lijekom Blincyto.
English: The safety profile of Blincyto was considered acceptable provided that recommendations on its use are observed.
Croatian: Sigurnosni profil lijeka Blincyto smatra se prihvatljivim uz uvjet da se prate preporuke za njegovu primjenu.
English: For more information about using Blincyto, see the package leaflet or contact your doctor or pharmacist.
Croatian: Za više informacija o primjeni lijeka Blincyto pogledajte uputu o lijeku ili se obratite liječniku ili ljekarniku.
English: Before receiving Blincyto, patients should be given medicines to prevent fever and reactions to the infusion.
Croatian: Prije nego što prime lijek Blincyto, bolesnicima treba dati lijekove za sprječavanje vrućice i reakcija na infuziju.
English: Side effects reported with Blincyto are carefully evaluated and any necessary action taken to protect patients.
Croatian: Nuspojave prijavljene za lijek Blincyto pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
English: ALL is rare, and Blincyto was designated an ‘orphan medicine' (a medicine used in rare diseases) on 24 July 2009.
Croatian: ALL je rijetka bolest, a lijek Blincyto dobio je status „lijeka za liječenje rijetkih i teških bolesti” 24. srpnja 2009.
English: Blincyto was given ‘conditional approval' but the company has provided more evidence about the medicine and the Agency has recommended that the Blincyto's marketing authorisation should no longer be conditional.
Croatian: Za lijek Blincyto izdano je „uvjetno odobrenje”, ali je tvrtka dostavila dodatne dokaze o lijeku te je Agencija preporučila ukidanje uvjetnog odobrenja za stavljanje lijeka Blincyto u promet.
English: The company that markets Blincyto will provide data from two studies looking at the safety and use of Blincyto in clinical practice.
Croatian: Tvrtka koja stavlja lijek Blincyto u promet dostavit će podatke iz dvaju ispitivanja usmjerenih na sigurnost primjene i upotrebu lijeka Blincyto u kliničkoj praksi.
English: Blincyto received a conditional marketing authorisation valid throughout the EU on 23 November 2015.
Croatian: Lijek Blincyto dobio je uvjetno odobrenje za stavljanje lijeka u promet koje vrijedi na prostoru EU-a od 23. studenoga 2015.
English: Blincyto is infused continuously during a treatment cycle of 4 weeks.
Croatian: Blincyto se kontinuirano primjenjuje infuzijom tijekom ciklusa liječenja od 4 tjedna.
English: As for all medicines, data on the use of Blincyto are continuously monitored.
Croatian: Kao i za sve lijekove, podatci o primjeni lijeka Blincyto kontinuirano se prate.
English: Patients who have no signs of cancer after 2 cycles may be treated with up to 3 additional cycles of Blincyto if the benefits outweigh the risks for the patient.
Croatian: Bolesnike koji nakon 2 ciklusa nemaju znakove raka moguće je dalje liječiti lijekom Blincyto do 3 dodatna ciklusa, ako koristi za bolesnika nadmašuju rizike.
English: The main measure of effectiveness was based on the percentage of patients whose ALL improved after 2 treatment cycles, measured as resolution of signs of leukaemia and complete or partial return of blood cell counts to normal.
Croatian: Glavno mjerilo djelotvornosti temeljilo se na postotku bolesnika u kojih se poboljšanje ALL-a postiglo nakon 2 ciklusa liječenja, mjereno kao povlačenje znakova leukemije te kao potpuno ili djelomično vraćanje broja krvnih stanica na normalnu vrijednost.
English: What are the risks associated with Blincyto?
Croatian: Koji su rizici povezani s lijekom Blincyto?
English: Patients lived for an average of around 6 months before the cancer came back, which could enable suitable patients to have a blood stem cell transplant.
Croatian: Vrijeme do povratka raka u bolesnika iznosilo je u prosjeku oko 6 mjeseci, što bi odgovarajućim bolesnicima moglo omogućiti presađivanje krvnih matičnih stanica.
English: The most serious side effects were infections, neutropenia with or without fever, neurological events (such as confusion, shaking, dizziness, numbness or tingling), cytokine release syndrome, and tumour lysis syndrome (a complication due to the breakdown of cancer cells).
Croatian: Najozbiljnije nuspojave bile su infekcije, neutropenija s vrućicom ili bez nje, neurološki događaji (kao što su smetenost, drhtanje, omaglica, utrnulost ili trnci), sindrom otpuštanja citokina i sindrom lize tumora (komplikacija koja nastaje zbog raspadanja stanica raka).
English: Blincyto can only be obtained with a prescription, and treatment should be started by a doctor who has experience in the treatment of patients with cancers of the blood.
Croatian: Blincyto se izdaje samo na liječnički recept, a liječenje smije započeti samo liječnik s iskustvom u liječenju osoba oboljelih od raka krvi.
English: For treatment of patients with minimal residual disease, the dose depends on the patient's bodyweight.
Croatian: Kod liječenja bolesnika s minimalnom rezidualnom bolešću, doza ovisi o bolesnikovoj tjelesnoj težini.
English: What is Blincyto and what is it used for?
Croatian: Što je Blincyto i za što se primjenjuje?
English: Why is Blincyto authorised in the EU?
Croatian: Zašto je lijek Blincyto odobren u EU-u?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Blincyto have also been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Blincyto nalaze se također u sažetku opisa svojstava lijeka i u uputi o lijeku.
English: The European Medicines Agency decided that Blincyto's benefits are greater than its risks and it can be authorised for use in the EU.
Croatian: Europska agencija za lijekove zaključila je da koristi od lijeka Blincyto nadmašuju s njim povezane rizike te da lijek može biti odobren za primjenu u Europskoj uniji.
English: An overview of Blincyto and why it is authorised in the EU
Croatian: Pregled informacija o lijeku Blincyto i zašto je odobren u EU-u
English: The company will also provide patients and healthcare professionals with educational materials on how to give Blincyto and how to manage risks with the medicine.
Croatian: Tvrtka će se također pobrinuti da bolesnici i zdravstveni radnici dobiju edukacijske materijale o tome kako se primjenjuje lijek Blincyto i kako postupati u pogledu rizika povezanih s lijekom.
English: Blincyto is used in patients who are ‘Philadelphia-chromosome-negative' which means that the patients' cancer cells do not have an abnormal chromosome called the Philadelphia chromosome, and in patients who have the protein CD19 on their cancer cells (CD19-positive).
Croatian: Blincyto se primjenjuje u bolesnika koji su „negativni na Philadelphia kromosom”, što znači da stanice raka tih bolesnika nemaju abnormalni kromosom koji se naziva Philadelphia kromosom te u bolesnika koji imaju protein CD19 na stanicama raka (pozitivni na protein CD19).
English: It also attaches to a protein (CD3) on T cells (another type of white blood cell).
Croatian: Djelatna tvar veže se i na protein (CD3) koji se nalazi na T‑lim focitim a (druga vrsta bijelih krvnih stan ica).
English: Patients may be treated for up to 3 additional treatment cycles, each one given after a 2-week treatment-free interval.
Croatian: Bolesnici se mogu liječiti još najviše 3 dodatna ciklusa liječenja, a svaki od njih slijedi nakon dvotjednog razdoblja bez liječenja.
English: How does Blincyto work?
Croatian: Kako djeluje Blincyto?
English: Blincyto is given by infusion (drip) into a vein using a pump device.
Croatian: Blincyto se daje u obliku infuzije (nakapavanja) u venu pomoću infuzijske pumpe.
English: Patients were given Blincyto for up to 5 treatment cycles.
Croatian: Bolesnici su primali lijek Blincyto do najviše 5 ciklusa liječenja.
English: Blincyto is also effective at removing residual cancer cells in adults who have been treated for B-precursor ALL and who are at high risk of the cancer coming back.
Croatian: Blincyto je također učinkovit za uklanjanje rezidualnih stanica raka u odraslih bolesnika koji su bili liječeni zbog ALL-a prekursora B limfocita i u kojih postoji visoki rizik od povratka raka.
English: In B-precursor ALL, certain cells that give rise to B cells (a type of white blood cell) multiply too quickly and eventually these abnormal cells replace normal blood cells.
Croatian: Kod akutne limfoblastične leukemije prekursora B limfocita, određene stanice iz kojih nastaju B limfociti (vrsta bijelih krvnih stanica) umnažaju se prebrzo i naposljetku te abnormalne stanice zamijene normalne krvne stanice.
English: The Agency noted that Blincyto is beneficial for high-risk adults and children with Philadelphia-chromosome-negative B-precursor ALL who have few therapeutic options and who generally have a poor prognosis.
Croatian: Agencija je uočila koristi od lijeka Blincyto u odraslih osoba i djece visokog rizika s ALL-om prekursora B limfocita negativnih na Philadelphia kromosom, koji imaju malo drugih terapijskih mogućnosti i u kojih je prognoza većinom loša.
English: In this study, Blincyto was not compared with any other treatment.
Croatian: U tom ispitivanju lijek Blincyto nije uspoređen ni s jednom drugom terapijom.
English: Each cycle of treatment is separated by a 2-week treatment-free interval.
Croatian: Nakon svakog ciklusa liječenja slijedi razdoblje bez liječenja u trajanju od 2 tjedna.
English: A study in 70 children aged 1 year and above with Philadelphia-chromosome-negative B-precursor ALL found that in 33% of patients treatment with Blincyto led to a resolution of the disease.
Croatian: U ispitivanju koje je uključivalo 70 djece s ALL-om prekursora B limfocita negativnih na Philadelphia kromosom u dobi od 1 godine i više, utvrđeno je da je liječenje lijekom Blincyto dovelo do povlačenja bolesti u 33 % bolesnika.
English: What benefits of Blincyto have been shown in studies?
Croatian: Koje su koristi od lijeka Blincyto utvrđene u ispitivanjima?
English: Blincyto must not be given to breastfeeding women.
Croatian: Blincyto se ne smije primjenjivati u dojilja.
English: The active substance in Blincyto, blinatumomab, is an antibody that has been designed to attach to a protein (CD19) found on B cells, including ALL cells.
Croatian: Djelatna tvar u lijeku Blincyto, blinatumomab, protutijelo je koje je namijenjeno vezivanju na protein (CD19) koji se nalazi na B limfocitima, uključujući stanice akutne limfoblastične leukemije.
English: How is Blincyto used?
Croatian: Kako se Blincyto primjenjuje?
English: Blincyto has been studied in one main study in 189 Philadelphia-chromosome-negative adults with Bprecursor ALL whose leukaemia had come back or had not improved with treatment.
Croatian: U jednom glavnom ispitivanju lijek Blincyto ispitivan je na 189 odraslih osoba s ALL-om prekursora B‑lim focita negativnih na Philadelphia krom osom , u kojih se leukem ija vratila ili se liječenjem nije postiglo poboljšanje.
English: Blincyto is also used in adults who have been treated for B-precursor ALL and have minimal residual disease (which means that they still have some detectable cancer cells in their body).
Croatian: Blincyto se primjenjuje i u odraslih osoba koje su bile podvrgnute liječenju ALL‑a prekursora B‑lim focita i im aju m inim alnu rezidualnu bolest (što znači da im se u tijelu još uvijek m ogu detektirati stanice raka).
English: For treatment of relapsed or refractory B-precursor ALL, the dose depends on the patient's bodyweight.
Croatian: U liječenju relapsne ili refraktorne akutne limfoblastične leukemije prekursora B‑lim focita doza ovisi o bolesnikovoj tjelesnoj težini.
English: Blincyto is a medicine used to treat a blood cancer called B-precursor acute lymphoblastic leukaemia (ALL) in patients above 1 year of age when the cancer has come back (relapsed) or has not improved with previous treatment (refractory).
Croatian: (ALL) prekursora B‑lim focita u bolesnika starijih od godinu dana u kojih se rak vratio (relaps) ili se prethodnim liječenjem nije postiglo poboljšanje (refraktoran).
English: Blincyto contains the active substance blinatumomab and is used on its own.
Croatian: Blincyto sadrži djelatnu tvar blinatumomab te se primjenjuje kao monoterapija.
English: For the full list of side effects of Blincyto, see the package leaflet.
Croatian: Potpuni popis nuspojava zabilježenih pri primjeni lijeka Blincyto potražite u uputi o lijeku.
English: Blincyto therefore acts as a ‘bridge' bringing T cells and B cells together and causing the T cells to release substances that eventually kill the cancerous B cells.
Croatian: Lijek Blincyto stoga djeluje kao „poveznica” koja spaja T‑lim focite i B‑ lim focite i potiče
English: Germany Glenmark Arzneimittel
Croatian: Njemačka Glenmark Arzneimittel
English: Zydus France
Croatian: Francuska Zydus France
English: Sweden Medical Valley Invest AB
Croatian: Švedska Medical Valley Invest AB
English: Germany Hexal Aktiengesellschaft
Croatian: Njemačka Hexal Aktiengesellschaft
English: Sanofi Aventis France
Croatian: Francuska Sanofi Aventis France
English: Teva Nederland B.V.
Croatian: Nizozemska Teva Nederland B.V.
English: Active Substance Strength Pharmaceutical Form
Croatian: Jačina Farmaceutski oblik
English: Annex IB: Products for which the marketing authorisations are recommended for suspension and marketing authorisation applications which do not satisfy the criteria for authorisation
Croatian: Prilog I.B: Lijekovi za koje se preporučuje privremena obustava odobrenja za stavljanje lijeka u promet i zahtjevi za odobrenje za stavljanje lijeka u promet koji ne ispunjavaju kriterije za davanje odobrenja
English: Annex IA: Medicinal products recommended for maintenance and marketing authorisation applications for which bioequivalence vis-à-vis the EU reference medicinal product has been established
Croatian: Prilog I.A: Lijekovi za koje se preporučuje zadržavanje odobrenja za stavljanje lijeka u promet i zahtjevi za odobrenje za stavljanje u promet lijekova za koje je utvrđena bioekvivalencija u odnosu na referentni lijek odobren u EU-u
English: amoxicillin mg
Croatian: amoksicilin mg
English: Medipha Sante AMOXICILLINE MEDIPHA 1 g amoxicillin
Croatian: Medipha Sante AMOXICILLINE MEDIPHA 1 g amoksicilin
English: Iceland Lyfis ehf.
Croatian: Lyfis ehf.
English: Teva Sante
Croatian: Francuska Teva Sante
English: Malacomp HEXAL junior atovaquone/ proguanil
Croatian: Malacomp HEXAL junior atovakvon/ progvanil
English: Annex I List of nationally authorised medicinal products and marketing authorisation applications
Croatian: Popis nacionalno odobrenih lijekova i zahtjeva za odobrenje za stavljanje lijeka u promet
English: Rasagiline Brown & Burk 1mg Tablets rasagiline
Croatian: Rasagiline Brown & Burk 1mg Tablets razagilin
English: Medipha Sante
Croatian: Francuska Medipha Sante
English: Rasagilin Micro Labs 1 mg Tabletten rasagiline
Croatian: Rasagilin Micro Labs 1 mg Tabletten razagilin
English: Pharmaceuticals, S.L.
Croatian: Pharmaceutica ls, S.L.
English: Amoxicilina Brown amoxicillin
Croatian: Amoxicilina Brown amoksicilin
English: EBASTINE ZENTIVA ebastine
Croatian: EBASTINE ZENTIVA ebastin
English: Orodispersible tablet
Croatian: Raspadljiva tableta za
English: EBASTINE BIOGARAN ebastine
Croatian: EBASTINE BIOGARAN ebastin
English: Saquinavir Accord 500 mg plėvele dengtos tabletės saquinavir
Croatian: Saquinavir Accord 500 mg plėvele dengtos tabletės sakvinavir
English: Celecoxib Medical Valley celecoxib
Croatian: Celecoxib Medical Valley celekoksib
English: Amoxicilline Authou amoxicillin
Croatian: Amoxicilline Authou amoksicilin
English: Sandoz Farmaceutica, S.A.
Croatian: Španjolska Sandoz Farmaceutica, S.A.
English: Sweden Orifarm Generics A/S
Croatian: Švedska Orifarm Generics A/S
English: Saquinavir Accord saquinavir
Croatian: Saquinavir Accord sakvinavir
English: Germany Hormosan Pharma
Croatian: Njemačka Hormosan Pharma
English: Celecoxib Hetero celecoxib
Croatian: Celecoxib Hetero celekoksib
English: Celecoxib Brill Pharma 100 mg and 200 mg cápsulas duras celecoxib
Croatian: Celecoxib Brill Pharma 100 mg and 200 mg cápsulas duras celekoksib
English: Saquinavir HEXAL 500 mg Filmtabletten saquinavir
Croatian: Saquinavir HEXAL 500 mg Filmtabletten sakvinavir
English: 10 mg Orodispersible tablet
Croatian: 10 mg Raspadljiva tableta za
English: Saquinavir Farmoz saquinavir
Croatian: Saquinavir Farmoz sakvinavir
English: Pensa Pharma, S.A.U.
Croatian: Španjolska Pensa Pharma, S.A.U.
English: Finland Sandoz A/S
Croatian: Sandoz A/S
English: Germany 1A Pharma GmbH
Croatian: Njemačka 1A Pharma GmbH
English: Sweden Sandoz A/S
Croatian: Švedska Sandoz A/S
English: Teva Pharma, S.L.U.
Croatian: Španjolska Teva Pharma, S.L.U.
English: Saquinavir Accord 500 mg film-coated tablets saquinavir
Croatian: Saquinavir Accord 500 mg film-coated tablets sakvinavir
English: Saquinavir saquinavir
Croatian: Saquinavir sakvinavir
English: Sweden Mylan AB
Croatian: Švedska Mylan AB
English: Germany Aristo Pharma GmbH
Croatian: Njemačka Aristo Pharma GmbH
English: Biogaran
Croatian: Francuska Biogaran
English: Amoxicillin Micro Labs 1000 mg amoxicillin
Croatian: Amoxicillin Micro Labs 1000 mg amoksicilin
English: Celecoxib
Croatian: celekoksib
English: Amoxicillin Micro Labs 750 mg amoxicillin
Croatian: Amoxicillin Micro Labs 750 mg amoksicilin
English: Abacavir / Lamivudine abacavir/ lamivudine
Croatian: Abacavir / Lamivudine abakavir/ lamivudin
English: 25 mg Capsule, hard Oral use
Croatian: 25 mg Kapsula, tvrda Kroz usta
English: Amoxicillin Micro Labs 250 mg amoxicillin
Croatian: Amoxicillin Micro Labs 250 mg amoksicilin
English: 20 mg Capsule
Croatian: 20 mg Kapsula
English: Industria Química Y Farmacéutica VIR, S.A.
Croatian: Španjolska Industria Química Y Farmacéutica
English: Irbesartan / Hydrochlorothiazide Micro Labs 300 mg /25 mg Filmtabletten irbesartan/ hydrochlorothiazide
Croatian: Irbesartan / Hydrochlorothiazide Micro Labs 300 mg /25 mg Filmtabletten irbesartan/ hidroklorotiazid
English: Denmark Orifarm Generics A/S
Croatian: Norveška Orifarm Generics A/S
English: 60 mg Capsule
Croatian: 60 mg Kapsula
English: 30 mg Capsule
Croatian: 30 mg Kapsula
English: Hydrochlorothiazide Micro Labs 150 mg/12.5 mg Filmtabletten irbesartan/ hydrochlorothiazide
Croatian: Hydrochlorothiazide Micro Labs 150 mg/12.5 mg Filmtabletten irbesartan/ hidroklorotiazid
English: Amoxicillin Micro Labs 500 mg amoxicillin
Croatian: Amoxicillin Micro Labs 500 mg amoksicilin
English: Celecoxib Glenmark 200 mg Hartkapseln celecoxib
Croatian: Celecoxib Glenmark 200 mg Hartkapseln celekoksib
English: Celecoxib Glenmark 100 mg Hartkapseln celecoxib
Croatian: Celecoxib Glenmark 100 mg Hartkapseln celekoksib
English: Celecoxib axcount 100 mg Hartkapseln celecoxib
Croatian: Celecoxib axcount 100 mg Hartkapseln celekoksib
English: Celecoxib axcount 200 mg Hartkapseln celecoxib
Croatian: Celecoxib axcount 200 mg Hartkapseln celekoksib